Abstract Number: 2955 • 2017 ACR/ARHP Annual Meeting
Does Guideline-Based Care Improve Outcomes That Matter to Patients? Tighter Control, Less Suffering, and Greater Well-Being over the Past Decade in Canadian RA Patients
Background/Purpose: Best practice recommendations can increase quality of care and improve clinical outcomes, however the impact of recommendations on outcomes that matter most to patients…Abstract Number: 1432 • 2016 ACR/ARHP Annual Meeting
The EULAR Systemic Sclerosis Impact of Disease Score – a New Patient-Reported Outcome Measure for Patients with Systemic Sclerosis Under Development
Background/Purpose: Patient reported outcome measures (PROM) are required as key outcomes in disease modifying therapeutic trials in systemic sclerosis (SSc). A PROM tool in SSc,…Abstract Number: 1598 • 2016 ACR/ARHP Annual Meeting
Olokizumab Treatment of Both Western and Asian Patients with Rheumatoid Arthritis Who Have Failed Anti-TNF Treatment Results in Sustained Improvements in Patient-Reported Outcomes
Background/Purpose: Rheumatoid arthritis (RA) has a high patient (pt) burden with significant impact on health-related quality of life. We report the effect of treatment with…Abstract Number: 1599 • 2016 ACR/ARHP Annual Meeting
Speed of Onset of Effect on Patient-Reported Outcomes Assessed through Daily Electronic Patient Diaries in the Baricitinib Phase 3 RA Clinical Program
Background/Purpose: Baricitinib (bari), an oral Janus kinase (JAK) 1/JAK2 selective inhibitor, has demonstrated clinical efficacy with a satisfactory safety profile when administered once daily in…Abstract Number: 1689 • 2016 ACR/ARHP Annual Meeting
Ixekizumab Provides Improvements through 52 Weeks in Physical Function, Quality of Life, and Work Productivity in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients with Active Psoriatic Arthritis
Background/Purpose: PsA has a negative impact on patients’ quality of life, physical function, and work productivity. Ixekizumab (IXE) is an IgG4 mAb that binds with…Abstract Number: 1692 • 2016 ACR/ARHP Annual Meeting
Validation of a Two-Question Patient Reported Outcome Measure for Psoriasis
Background/Purpose: While the psoriasis area and severity index (PASI) is the most commonly used assessment tool for psoriasis severity, it has been criticized for its…Abstract Number: 2003 • 2016 ACR/ARHP Annual Meeting
Validation of the ASAS Health Index: Results of a Multicenter International Study in 23 Countries
Background/Purpose: The ASAS Health Index (ASAS HI) was developed to measure functioning and health in patients with spondyloarthritis (SpA) aiming to better define the impact…Abstract Number: 95 • 2016 ACR/ARHP Annual Meeting
An Analysis of Malpractice Litigation in Rheumatology
Background/Purpose: Medicine is an increasingly more litigious environment, and the probability of a practitioner facing a medical malpractice claim is high. Given the tumultuous liability…Abstract Number: 2041 • 2016 ACR/ARHP Annual Meeting
Validity and Reliability of Patient Reported Outcomes Measurement Information System (PROMIS®) Global Health Short Form in Patients with SLE
Background/Purpose: The measurement of patient reported outcomes (PROs) is a growing priority for performance improvement in clinical care of chronic conditions such as SLE. Measuring…Abstract Number: 100 • 2016 ACR/ARHP Annual Meeting
Patient Support Program for Adalimumab-Treated Patients in Brazil: Impact on Patients’ Adherence and Persistence
Background/Purpose: The Brazilian public healthcare system covers treatment with adalimumab for rheumatoid arthritis, Crohn's disease, ankylosing spondylitis and psoriatic arthritis, in line with local guidelines.…Abstract Number: 2250 • 2016 ACR/ARHP Annual Meeting
A Real World View of Rheumatoid Arthritis Patients Treated with Advanced Therapies: Comparing Patient Profiles and Outcomes
Background/Purpose: Advanced therapies including bDMARDs and tofacitinib have been shown to help control disease progression in rheumatoid arthritis (RA) and reduce joint damage. The aim…Abstract Number: 212 • 2016 ACR/ARHP Annual Meeting
Pegloticase Provides Clinical Benefit in Patients with Chronic Refractory Gout Who Did Not Meet the Clinical Trial Biochemical Definition of Response
Background/Purpose: Pegloticase is a recombinant uricase conjugated to polyethylene glycol approved for the treatment of chronic refractory gout refractory. The pivotal clinical trials for pegloticase…Abstract Number: 2515 • 2016 ACR/ARHP Annual Meeting
Patient-Reported Outcomes in Two Randomized, Controlled Trials (RCTs) in Patients with Rheumatoid Arthritis (RA) Treated with Tocilizumab (TCZ) Monotherapy Compared with Methotrexate (MTX) or Adalimumab (ADA)
Background/Purpose: Patient-reported outcomes (PROs) are important measures when determining response to therapy in patients with RA. Previous RCTs have shown that TCZ monotherapy is superior…Abstract Number: 546 • 2016 ACR/ARHP Annual Meeting
Boolean-Based Remission in Rheumatoid Arthritis Using Physician Versus Patient Global Assessment: Differences in Ultrasonographic Disease Activities, Sustainabilities, and Relapse Rates
Background/Purpose: Patient global assessment (PtGA), despite not being exclusively related to disease activity, is included in Boolean-based remission (BR) criteria for RA. This study evaluated…Abstract Number: 2548 • 2016 ACR/ARHP Annual Meeting
Single 1g Infusion Vs Double 1g Infusion of Rituximab in Rheumatoid Arthritis in a Large Teaching Hospital: Potential Clinical Benefits and Financial Savings
Background/Purpose: Recent trial data from Mariette et al. investigating a single-dose 1g rituximab regimen as opposed to a double-dose 1g rituximab regimen in patients with…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 9
- Next Page »